Gemfibrozil for Nicotine Smoking Cessation (GEMNIC)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02638597
Recruitment Status :
First Posted : December 23, 2015
Results First Posted : February 1, 2019
Last Update Posted : February 1, 2019
University of Texas Southwestern Medical Center
Information provided by (Responsible Party):
Madhukar H. Trivedi, MD, University of Texas Southwestern Medical Center
Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion
Gemfibrozil: FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.